Literature DB >> 7859157

Production and purification of hybrid Ty-VLPs.

N R Burns1, J E Gilmour, S M Kingsman, A J Kingsman, S E Adams.   

Abstract

This article describes how pure Ty-VLPs (virus-like particles) can be prepared from hybrid Ty-VLPs. Many different hybrid Ty-VLPs have been produced and may be easily purified. Since the sedimentation properties of different hybrid Ty-VLPs are similar, a simple purification process can be used for any VLP. This fast, versatile, and easy process allows for the production of a variety of recombinant proteins.

Mesh：

Substances：

Year:  1994        PMID： 7859157     DOI： 10.1007/bf02921554

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN： 1073-6085            Impact factor:   2.695


  5 in total

1.  The production of hybrid Ty:IFN virus-like particles in yeast.

Authors:  M H Malim; S E Adams; K Gull; A J Kingsman; S M Kingsman
Journal:  Nucleic Acids Res       Date:  1987-09-25       Impact factor: 16.971

2.  A novel method for the purification of HIV-1 p24 protein from hybrid Ty virus-like particles (Ty-VLPs).

Authors:  J E Gilmour; J M Senior; N R Burns; M P Esnouf; K Gull; S M Kingsman; A J Kingsman; S E Adams
Journal:  AIDS       Date:  1989-11       Impact factor: 4.177

Review 3.  Polyvalent recombinant antigens: a new vaccine strategy.

Authors:  S M Kingsman; A J Kingsman
Journal:  Vaccine       Date:  1988-08       Impact factor: 3.641

4.  The expression of hybrid HIV:Ty virus-like particles in yeast.

Authors:  S E Adams; K M Dawson; K Gull; S M Kingsman; A J Kingsman
Journal:  Nature       Date:  1987 Sep 3-9       Impact factor: 49.962

5.  HIV-1 TAT "activates" presynthesized RNA in the nucleus.

Authors:  M Braddock; A Chambers; W Wilson; M P Esnouf; S E Adams; A J Kingsman; S M Kingsman
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582
  5 in total
  3 in total

1.  Virus-like particles as vaccine adjuvants.

Authors:  S C Gilbert
Journal:  Mol Biotechnol       Date:  2001-10       Impact factor: 2.695

2.  Immune response modulation by recombinant peptides expressed in virus-like particles.

Authors:  E V Svirshchevskaya; L Alekseeva; A Marchenko; N Viskova; T M Andronova; S V Benevolenskii; V P Kurup
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

3.  Exploiting the yeast L-A viral capsid for the in vivo assembly of chimeric VLPs as platform in vaccine development and foreign protein expression.

Authors:  Frank Powilleit; Tanja Breinig; Manfred J Schmitt
Journal:  PLoS One       Date:  2007-05-02       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.